your partner in preclinical research

Latest Posts

> 2017 Mar

Urosphere will be present at the European Association of Urology congress 2017

Urosphere will present two posters at the 32st annual EAU congress (24-28 March 2017).     

Read more

> 2016 May

Urosphere presented two posters at ERA-EDTA congress

Urosphere presented two posters in collaboration with Solid Drug Development at the 53rd annual ERA-EDTA congress: Effect of JNK inhibitor in a rat model of renal ischemia-reperfusion injury (link) Effects of JNK inhibitor on puromycin aminonucleoside-induced nephropathy in rats (link) Please click on links next to the posters titles to see them.

Read more
EAU 2016

> 2016 Feb

Urosphere will be present at the European Association of Urology congress 2016

Urosphere will be present at the International Continence Society 2017 will present two posters at the 31st annual EAU congress (13 March 2016 at 12:45 PM, room 14a): Immunotherapy to treat Bladder Painful Syndrome Development and validation of a clinically-relevant chronic model of Interstitial Cystitis / Bladder Painful Syndrome It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.

Read more

> 2016 Jan

Urosphere will attend the toulouse oncoweek, to be held in toulouse, france, february 03-05, 2016.

We will have an oral communication on "Optical imaging in preclinical tumour models: helpful or pitfall?” on Friday, February 5th, 13:00-14:15
If you wish to meet Urosphere's managers during the meeting, please contact us.

Read more
Urosphere Ambiotis

> 2016 Jan

Urosphere and Ambiotis sign a strategic collaboration agreement

Urosphere and Ambiotis another Contract Research Organization, based in Toulouse, France announce a strategic partnership to broaden and strenghten their respective activities. Under this agreement, the two companies intend to combine their skills to offer an even more integrated approach to their customers. UROSPHERE will indeed bring its expertise in building physiological and pathological animal models within the uro-genital, gastro-intestinal and oncological areas while Ambiotis will offer its expertise in the molecular characterization of such models (inflammatory and pain mediators).

Read more